Literature DB >> 35294845

The microRNA-cell surface proteoglycan axis in cancer progression.

Zoi Piperigkou1,2, Kyriaki Tzaferi1, George Makrokanis1, Konstantina Cheli1, Nikos K Karamanos1,2.   

Abstract

Proteoglycans consist one of the major extracellular matrix class of biomolecules that demonstrate nodal roles in cancer progression. Modern diagnostic and therapeutic approaches include proteoglycan detection and pharmacological targeting in various cancer types. Proteoglycans orchestrate critical signaling pathways for cancer development and progression through dynamic interactions with matrix components. It is well established that the epigenetic signatures of cancer cells play critical role in guiding their functional properties and metastatic potential. Secreted microRNAs (miRNAs) reside in a complex network with matrix proteoglycans, thus affecting cell-cell and cell-matrix communication. This mini-review aims to highlight current knowledge on the cell-surface proteoglycan-mediated signaling cascades that regulate miRNA biogenesis in cancer. Moreover, the miRNA-mediated proteoglycan regulation during cancer progression and mechanistic aspects on the way that proteoglycans affect miRNA expression are presented. Recent advances on the role of cell surface proteoglycans in exosome biogenesis and miRNA packaging and expression are also discussed.

Entities:  

Keywords:  cancer progression; extracellular matrix; glypicans; miRNAs; syndecans

Mesh:

Substances:

Year:  2022        PMID: 35294845     DOI: 10.1152/ajpcell.00041.2022

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  2 in total

1.  ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo.

Authors:  Zoi Piperigkou; Anastasios Koutsandreas; Marco Franchi; Vasiliki Zolota; Dimitrios Kletsas; Alberto Passi; Nikos K Karamanos
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

2.  Editorial: Molecules of the extracellular matrix as cancer targets.

Authors:  Nikos K Karamanos; Martin Götte; Alberto Passi
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.